Y-90 radioembolization for kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a procedure called Y-90 radioembolization for patients with kidney cancer tumors larger than 4 cm who cannot have or choose not to have surgery. The treatment delivers tiny radioactive beads through a blood vessel to the tumor to destroy cancer cells while limiting damage to healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a kidney cancer tumor larger than 4 cm that has not spread to the kidney vein or main blood vessel.
- You are not able to have or choose not to have standard surgery to remove the tumor.
- Your liver and blood counts are within acceptable ranges as determined by blood tests.
- You have no evidence that the cancer has spread to other parts of your body.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called Y90 radioembolization for people with early-stage kidney cancer who cannot have surgery or ablation. Tiny radioactive beads are delivered through a catheter to the tumor's blood supply to destroy it from the inside.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
This trial tests a targeted radiation treatment (Y-90 radioembolization) given before surgery for colorectal cancer that has spread to the liver. The goal is to shrink liver tumors enough to make them removable and improve the chance of a successful surgery.
This trial tests a treatment called yttrium-90 carbon microsphere radioembolization for people with liver cancer that has been previously treated. Tiny radioactive beads are delivered directly to the tumor through the blood vessels to destroy cancer cells from inside. This may be an option if your liver cancer has not spread beyond the liver and you can tolerate the procedure.
This study looks at how well Y90 “radioembolization” treatment delivers radiation and how much radiation reaches your body. If you can safely get extra PET/CT scans and blood tests around your treatment, you may be invited to participate.
This trial tests whether adding radioactive Y-90 microspheres (tiny beads that deliver radiation directly to liver tumors) to standard chemo (FOLFIRI and bevacizumab) can help people with advanced colorectal cancer that has spread only to one lobe of the liver, when the first treatment stopped working. The goal is to slow down tumor growth.
Hear when a new Radioembolization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.